Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shuhaiber, S.
Right arrow Articles by Koren, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shuhaiber, S.
Right arrow Articles by Koren, G.
NEUROLOGY 1998;51:581-583
© 1998 American Academy of Neurology

Pregnancy outcome following first trimester exposure to sumatriptan

S. Shuhaiber, BSc, A. Pastuszak, MSc, B. Schick, RNC, D. Matsui, MD, G. Spivey, MS, J. Brochu and G. Koren, MD

From The Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics and Research Institute, The Hospital for Sick Children and the University of Toronto (Dr. Koren, and S. Shuhaiber and A. Pastuszak), Ontario; Pennsylvania Healthline (B. Schick), Philadelphia, PA; Fetal Risk Assessment Program, Children's Hospital of Western Ontario (Dr. Matsui), London, Ontario, Canada; and Connecticut Pregnancy Exposure Information Service, Division of Human Genetics University of Connecticut Health Center (G. Spivey and J. Brochu), Farmington, CT.

Address correspondence and reprint requests to Dr. Gideon Koren, Division of Clinical Pharmacology/Toxicology, The Hospital For Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.

We prospectively compared pregnancy outcome after exposure to sumatriptan with that of disease-matched controls and nonteratogen controls. There were no differences in the rates of live births, spontaneous abortions, therapeutic abortions, or major birth defects among the three groups. This first prospective report suggests that the use of sumatriptan during organogenesis is not associated with an apparent increased risk of major birth defects.

Received December 3, 1997. Accepted in final form March 13, 1998.




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
E. W Evans and K. C Lorber
Use of 5-HT1 Agonists in Pregnancy
Ann. Pharmacother., April 1, 2008; 42(4): 543 - 549.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. L Hilaire, L B. Cross, and S. F Eichner
Treatment of Migraine Headaches with Sumatriptan in Pregnancy
Ann. Pharmacother., October 1, 2004; 38(10): 1726 - 1730.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
A. Einarson, B. Fatoye, M. Sarkar, S. V. Lavigne, J. Brochu, C. Chambers, P. Mastroiacovo, A. Addis, D. Matsui, L. Schuler, et al.
Pregnancy Outcome Following Gestational Exposure to Venlafaxine: A Multicenter Prospective Controlled Study
Am J Psychiatry, October 1, 2001; 158(10): 1728 - 1730.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.